1. Scrip
  2. >>Business
  3. >>Deals

Sanofi Will Employ Adagene’s Technology For Precision Targeting In Cancer

 
• By Joseph Haas

Sanofi will pay $17.5m up front to license candidates developed with Adagene’s SAFEbody platform, which can mask antibodies, enabling them to reach cancer targets in the tumor microenvironment.

Tumor microenvironment
Adagene's technology masks antibodies until activated by the tumor microenvironment • Source: Alamy

Who: Sanofi/Adagene

What: China’s Adagene will apply its SAFEbody platform technology to Sanofi’s antibody

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business